

Jorrit De Waele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7181017/publications.pdf>

Version: 2024-02-01

24
papers

1,118
citations

471509

17
h-index

713466

21
g-index

25
all docs

25
docs citations

25
times ranked

2034
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential and controversy of targeting STAT family members in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 41-56.	9.6	226
2	Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs. , 2015, 146, 120-131.		134
3	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , 2019, 11, 1597.	3.7	77
4	3D culture of murine neural stem cells on decellularized mouse brain sections. <i>Biomaterials</i> , 2015, 41, 122-131.	11.4	75
5	Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. <i>Oncolmunology</i> , 2017, 6, e1261241.	4.6	67
6	Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. <i>Redox Biology</i> , 2021, 42, 101949.	9.0	63
7	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. <i>Oncotarget</i> , 2017, 8, 56968-56979.	1.8	59
8	Cold atmospheric plasma treatment of melanoma and glioblastoma cancer cells. <i>Plasma Processes and Polymers</i> , 2016, 13, 1195-1205.	3.0	57
9	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1 α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. <i>Cancers</i> , 2018, 10, 126.	3.7	43
10	Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. <i>Oncotarget</i> , 2017, 8, 89722-89735.	1.8	43
11	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	8.6	42
12	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. <i>Oncolmunology</i> , 2018, 7, e1407899.	4.6	38
13	Clinically Relevant Chemotherapeutics Have the Ability to Induce Immunogenic Cell Death in Non-Small Cell Lung Cancer. <i>Cells</i> , 2020, 9, 1474.	4.1	37
14	Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. <i>Cells</i> , 2021, 10, 2936.	4.1	35
15	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	4.8	28
16	Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. <i>Clinical and Translational Immunology</i> , 2020, 9, e1165.	3.8	26
17	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. <i>British Journal of Cancer</i> , 2020, 123, 752-761.	6.4	25
18	The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. <i>Cancers</i> , 2021, 13, 282.	3.7	18

#	ARTICLE	IF	CITATIONS
19	Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. International Journal of Molecular Sciences, 2019, 20, 4182.	4.1	11
20	Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update. International Journal of Molecular Sciences, 2021, 22, 1807.	4.1	8
21	Immuno-PET Molecular Imaging of RANKL in Cancer. Cancers, 2021, 13, 2166.	3.7	3
22	OA02.07 Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S249-S250.	1.1	0
23	Abstract 3715A: Effusions of mesothelioma patients: What's in it for immunotherapy. , 2017, , .		0
24	Molecular Docking Study of Flavonoids to Block the Aryl Hydrocarbon Receptor. , 0, , .		0